Study to Evaluate the Safety and Efficacy of Dietary Supplement Anatabloc in Reducing Daily Smokers' Urge to Smoke

A Single Center, Single-Blind, Randomized, Crossover Pilot Study to Evaluate the Safety and Effects of Anatabloc™, a Dietary Supplement, in Reducing the Urge to Smoke in Daily Smokers Followed by an Open-Label Extension

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01428310

Enrollment

109

Registered

2011-09-02

Start date

2011-09-30

Completion date

2011-12-31

Last updated

2015-10-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Smoking, Tobacco Dependence, Tobacco Use Disorder

Keywords

dietary supplement, nutraceutical

Brief summary

This study will consist of 2 phases. Phase 1 will be a one day crossover study to see the effects of study product on a smoker's desire to smoke, measured by changes in scores on questionnaires given over time. Phase 2 will be a two-week extension, in which subjects will self-administer the study product and visit the study site for assessment of desire to smoke and collection of samples for the evaluation of smoking-related biomarkers.

Interventions

DIETARY_SUPPLEMENTAnatabloc(TM)

one dissolvable bit, one time, after a period of abstinence from smoking

DIETARY_SUPPLEMENTCigRx(R)

one dissolvable bit, one time, after a period of abstinence from smoking

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

23 Years to 72 Years

Healthy volunteers

Yes

Inclusion criteria

* healthy adult smokers * using at least 1 pack of cigarettes per day, for at least 5 years

Exclusion criteria

* allergy to study product components

Design outcomes

Primary

Measure	Time frame	Description
effect on subject's craving to smoke	5 hours	craving is assessed by changes in questionnaire answers over time

Secondary

Measure	Time frame	Description
adverse events related to study product	5 hours	collection of information on adverse events related to study product

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026